New Lung Cancer Campaign Launched

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 12
Volume 10
Issue 12

NEW YORK-In a recent Cancer Care, Inc. survey, 44% of lung cancer patients said they feel they are treated differently than people with other cancers. Even more medical professionals surveyed (77%) said they believe people with lung care are often stigmatized.

NEW YORK—In a recent Cancer Care, Inc. survey, 44% of lung cancer patients said they feel they are treated differently than people with other cancers. Even more medical professionals surveyed (77%) said they believe people with lung care are often stigmatized.

When asked why they felt stigmatized, patients said there is a marked reluctance on the part of celebrities to identify themselves as patients, which has resulted in poor fund-raising efforts and little publicity. Others feel blamed because most lung cancer cases (90%) are smoking related, yet 10% of patients never smoked.

To help decrease this culture of blame, a campaign known as It’s Time to Focus on Lung Cancer has launched a website www.lungcancer.org for patients, loved ones, and health care professionals, as well as a toll-free lung cancer information line at 1-877-646-LUNG (5864).

Actress S. Epatha Merkerson, who plays Lt. Anita Van Buren on NBC’s drama Law & Order, is lending her support to the campaign. Two of Ms. Merkerson’s best friends died of the disease. "We no longer have the right to remain silent about lung cancer," she said.

The campaign is being promoted nationally by Cancer Care, the Oncology Nursing Society, The Wellness Community, and The CHEST Foundation. 

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
Related Content